Drugs / Ginsenoside Rg3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01757366 | Dec 2012 → Jan 2016 | — | Hebei Tumor Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04523467 | Dec 2020 → Dec 2022 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Unknown | No outcome recorded |
| — | NCT01717066 | Apr 2012 → Dec 2014 | hepatocellular carcinoma | ShenFeng | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginsenoside Rg3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01757366 ↗ |
| Action | Inhibit | “reduce the expression of programmed cell death ligand 1 (PD-L1)” NCT04523467 ↗ |
| Route | Oral | “20mg 2/day po” NCT01757366 ↗ |